Clinical Trials Browser

Approved for marketing × Leukemia, Myeloid, Acute × Clear all

NCT03070093 2021-04-20

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Approved for marketing

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03245424 2018-07-24

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Approved for marketing

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01869803 2018-03-02

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Approved for marketing

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute